The U.S. FDA approved CASGEVY, a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia in patients 12 years and older.
AI Assistant
CRISPR THERAPEUTICS AG
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.